NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
New test fills unmet need for faster AML biomarker testing, expanding
“AML Express enhances our hematologic portfolio by addressing the clinical need for faster testing that informs critical treatment decisions,” said
AML accounts for about 1 out of 3 leukemias in adults. It is an aggressive disease that often develops and progresses rapidly over a few weeks, making access to timely and accurate diagnostic and prognostic information critical for patient care. With a turnaround time of just three to four days, AML Express delivers a time- and cost-effective alternative to traditional single-gene testing methods.
The panel includes an extensive list of genes selected for their clinical relevance in AML, covering DNA and RNA alterations, and is intended to be used in conjunction with clinical features and other laboratory results. AML Express simplifies the decision-making process for clinicians, facilitates patient enrollment in clinical trials, and supports the development of personalized treatment strategies.
“Patients with newly diagnosed acute myeloid leukemia are extremely ill at diagnosis and are at risk of life-threatening complications before initiating treatment,” said Dr.
AML Express aligns with the latest guidelines from the European LeukemiaNet, adopted by the National Comprehensive Cancer Network (NCCN), and the World Health Organization Classification for Hematolymphoid Tumors (5th edition). The new panel expands
About
Headquartered in
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “plan,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241008921520/en/
Investor Contact
kendra.sweeney@neogenomics.com
Media Contact
asampson@sampsonprgroup.com
Source: